ES2056817T5 - Transformacion de trichoderma. - Google Patents

Transformacion de trichoderma.

Info

Publication number
ES2056817T5
ES2056817T5 ES87303834T ES87303834T ES2056817T5 ES 2056817 T5 ES2056817 T5 ES 2056817T5 ES 87303834 T ES87303834 T ES 87303834T ES 87303834 T ES87303834 T ES 87303834T ES 2056817 T5 ES2056817 T5 ES 2056817T5
Authority
ES
Spain
Prior art keywords
trichoderma
transformation
vector system
secretion
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87303834T
Other languages
English (en)
Other versions
ES2056817T3 (es
Inventor
Jonathan Knowles
Anu Marjukka Harkki
Helena Nevalainen
Merja Penttila
Mogens Trier Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALTIA GROUP Ltd
Original Assignee
ALTIA GROUP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10597131&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2056817(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ALTIA GROUP Ltd filed Critical ALTIA GROUP Ltd
Application granted granted Critical
Publication of ES2056817T3 publication Critical patent/ES2056817T3/es
Publication of ES2056817T5 publication Critical patent/ES2056817T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6483—Chymosin (3.4.23.4), i.e. rennin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01091—Cellulose 1,4-beta-cellobiosidase (3.2.1.91)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23004—Chymosin (3.4.23.4), i.e. rennin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

SE HA DESARROLLADO UN SISTEMA PARA TRASNFORMACION DE TRICHODERMA. EL SISTEMA VECTOR PUEDE USARSE PARA ELEVADA EXPRESION Y SECRECION DE PROTEINAS EN TRICHODERMA POR TRANSFORMACION DE UNA CEPA ADECUADA DE TRICHODERMA CON EL SISTEMA VECTOR QUE CONTIENE UN GEN PARA LA PROTEINA DESEADA.
ES87303834T 1986-04-30 1987-04-29 Transformacion de trichoderma. Expired - Lifetime ES2056817T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868610600A GB8610600D0 (en) 1986-04-30 1986-04-30 Transformation of trichoderma

Publications (2)

Publication Number Publication Date
ES2056817T3 ES2056817T3 (es) 1994-10-16
ES2056817T5 true ES2056817T5 (es) 2002-05-01

Family

ID=10597131

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87303834T Expired - Lifetime ES2056817T5 (es) 1986-04-30 1987-04-29 Transformacion de trichoderma.

Country Status (10)

Country Link
EP (1) EP0244234B2 (es)
JP (2) JP2702924B2 (es)
AT (1) ATE91714T1 (es)
DE (1) DE3786592T3 (es)
DK (1) DK175814B1 (es)
ES (1) ES2056817T5 (es)
FI (1) FI108358B (es)
GB (1) GB8610600D0 (es)
IE (1) IE60428B1 (es)
NO (1) NO871785L (es)

Families Citing this family (535)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320960A (en) * 1992-04-03 1994-06-14 Genencor International, Inc. Method of preparing solution enriched in xylanase using low molecular weight alcohol, organic salt and inorganic salt
US5780292A (en) * 1987-04-29 1998-07-14 Alko Group Ltd. Production of phytate degrading enzymes in trichoderma
US5298405A (en) * 1986-04-30 1994-03-29 Alko Limited Enzyme preparations with recombinantly-altered cellulose profiles and methods for their production
US5610034A (en) * 1987-04-29 1997-03-11 Alko Group Ltd. Immunoglobulin production by trichoderma
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
EP0406314B1 (en) * 1988-03-24 1993-12-01 Novo Nordisk A/S A cellulase preparation
CA1333777C (en) * 1988-07-01 1995-01-03 Randy M. Berka Aspartic proteinase deficient filamentous fungi
CA1341226C (en) * 1988-08-16 2001-05-01 Wim Van Hartingsveldt Gene replacement as a tool for the construction of aspergillus strains
FR2649120B1 (fr) * 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5120463A (en) * 1989-10-19 1992-06-09 Genencor International, Inc. Degradation resistant detergent compositions based on cellulase enzymes
US5688290A (en) * 1989-10-19 1997-11-18 Genencor International, Inc. Degradation resistant detergent compositions based on cellulase enzymes
US5837515A (en) * 1990-05-16 1998-11-17 Alko-Yhtiot Oy Enzyme preparations and methods for their production
FI903443A (fi) * 1990-07-06 1992-01-07 Valtion Teknillinen Framstaellning av lackas genom rekombinantorganismer.
WO1992001797A1 (en) * 1990-07-16 1992-02-06 Oy Alko Ab IMMUNOGLOBULIN PRODUCTION BY $i(TRICHODERMA)
US5246853A (en) * 1990-10-05 1993-09-21 Genencor International, Inc. Method for treating cotton-containing fabric with a cellulase composition containing endoglucanase components and which composition is free of exo-cellobiohydrolase I
US5328841A (en) * 1990-10-05 1994-07-12 Genencor International, Inc. Methods for isolating EG III cellulase component and EG III cellulase in polyethylene glycol using inorganic salt and polyethylene glycol
US5650322A (en) * 1990-10-05 1997-07-22 Genencor International, Inc. Methods for stonewashing fabrics using endoglucanases
US5525507A (en) * 1990-10-05 1996-06-11 Genencor International, Inc. Methods for treating cotton-containing fabric with cellulase composition containing endoglucanase component and which is free of all CBH I component
US5290474A (en) * 1990-10-05 1994-03-01 Genencor International, Inc. Detergent composition for treating cotton-containing fabrics containing a surfactant and a cellulase composition containing endolucanase III from trichoderma ssp
US5654193A (en) * 1990-10-05 1997-08-05 Genencor International, Inc. Methods for treating cotton containing fabrics with cellulase
CA2093422C (en) * 1990-10-05 2001-04-03 DETERGENT COMPOSITIONS CONTAINING LOW CBH I CONTENT CELLULASE COMPOSITIONS
DK0562003T4 (en) * 1990-12-10 2015-07-13 Danisco Us Inc Improved saccharification of cellulose by cloning and amplification of.-Glucosidase gene from Tricodermareesei
EP0575462B1 (en) * 1991-03-22 1995-06-07 Gist-Brocades B.V. A process for producing chymosin
AU678356B2 (en) * 1992-05-01 1997-05-29 Genencor International, Inc. Methods for treating cotton-containing fabrics with CBH I enriched cellulase
WO1994003072A1 (en) * 1992-07-31 1994-02-17 Panlabs Incorporated Recombinant cells, dna constructs, vectors and methods for expressing phytate degrading enzymes in desired ratios
US5665585A (en) * 1992-09-03 1997-09-09 Alko-Yhiot Oy Recombinant production of glucoamylase P in trichoderma
GB9400623D0 (en) * 1994-01-14 1994-03-09 Univ Leeds Exploitation of the cellulase enzyme complex of neurospora
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US7816129B2 (en) 1994-07-29 2010-10-19 Ab Enzymes Gmbh Production and secretion of proteins of bacterial origin in filamentous fungi
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5700686A (en) * 1995-06-06 1997-12-23 Iogen Corporation Protease-treated and purified cellulase compositions and methods for reducing backstaining during enzymatic stonewashing
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
CA2241564C (en) 1996-01-08 2013-09-03 Genentech, Inc. Wsx receptor and ligands
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
DK0942992T3 (da) 1997-01-31 2007-07-02 Genentech Inc O-fucosyltransferase
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
PT973804E (pt) 1997-04-07 2007-03-30 Genentech Inc Anticorpos anti-vegf
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1630168B1 (en) 1997-08-27 2011-04-13 Novartis Vaccines and Diagnostics, Inc. Molecular mimetics of meningococcal B peptides
IL135704A (en) 1997-10-29 2008-04-13 Genentech Inc Method for the diagnosis of cancerous growth of cells by identifying the secreted polypeptide WISP-1 affected by WNT-1
CA2306450C (en) 1997-10-29 2012-07-10 Genentech, Inc. Polypeptides and nucleic acids encoding same
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
DE69939599D1 (de) 1998-12-16 2008-10-30 Novartis Vaccines & Diagnostic MENSCHLICHE CYCLIN-ABHÄNGIGE KINASE (hPNQALRE)
EP1484338B1 (en) 1998-12-22 2007-02-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
EP1978029A3 (en) 1999-06-15 2008-10-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
JP2003527833A (ja) 1999-10-14 2003-09-24 クロンテック・ラボラトリーズ・インコーポレーテッド 花虫類に由来する発色団／蛍光体、およびそれらの使用法
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897947B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
ES2311016T3 (es) 2000-01-10 2009-02-01 Novartis Vaccines And Diagnostics, Inc. Genes expresados diferencialmente en cancer de mama.
WO2004043361A2 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
EP1383881A2 (en) 2000-06-26 2004-01-28 Novozymes A/S Lipolytic enzymes from strains of fusarium and acremonium
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU8571901A (en) 2000-09-05 2002-03-22 Novozymes As Lipoxygenase
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
FI120310B (fi) 2001-02-13 2009-09-15 Valtion Teknillinen Parannettu menetelmä erittyvien proteiinien tuottamiseksi sienissä
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
DK1383874T3 (da) 2001-04-20 2010-05-03 Novozymes As Varianter af lipogygenase og deres anvendelse
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
ATE522623T1 (de) 2001-06-20 2011-09-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
BR0212070A (pt) 2001-08-29 2004-09-28 Genentech Inc ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
KR20040039444A (ko) 2001-09-27 2004-05-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인간 응고 인자 ⅶ 폴리펩티드
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
ZA200700168B (en) 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
WO2003054158A2 (en) 2001-12-19 2003-07-03 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
CA2471431A1 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003243400B2 (en) 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2263691T3 (da) 2002-07-15 2012-10-22 Hoffmann La Roche Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
DE60335552D1 (de) 2002-09-11 2011-02-10 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
EP2116551A1 (en) 2002-09-11 2009-11-11 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1543038B2 (en) 2002-09-11 2020-08-05 Genentech, Inc. Protein purification
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
KR20070055625A (ko) 2002-12-16 2007-05-30 제넨테크, 인크. 이뮤노글로불린 변이체 및 이들의 용도
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2004081229A2 (en) 2003-03-12 2004-09-23 Genentech, Inc. Use of bv8 and/or eg-vegf to promote hematopoiesis
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
JP2006524495A (ja) 2003-04-28 2006-11-02 ノボザイムス アクティーゼルスカブ ホスホリパーゼおよびそれを製造する方法
KR20200034817A (ko) 2003-05-30 2020-03-31 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
EP2368909A1 (en) 2003-06-12 2011-09-28 Eli Lilly and Company GLP-1 analog fusion proteins
NZ544317A (en) 2003-07-08 2009-05-31 Genentech Inc IL-17 A/F heterologous polypeptides and therapeutic uses thereof
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
CN102174490B (zh) 2003-11-21 2016-09-28 丹尼斯科美国公司 颗粒淀粉水解酶在木霉菌中的表达和从颗粒淀粉底物产生葡萄糖的方法
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
SG135176A1 (en) 2004-02-02 2007-09-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8097445B2 (en) 2004-03-25 2012-01-17 Danisco Us Inc. Exo-endo cellulase fusion protein
CA2560588A1 (en) 2004-03-25 2005-10-06 Genencor International, Inc. Cellulase fusion protein and heterologous cellulase fusion construct encoding the same
ES2407465T3 (es) 2004-03-29 2013-06-12 Galpharma Co., Ltd. Nueva proteína galectina 9 modificada y uso de la misma
WO2005095457A2 (en) 2004-03-30 2005-10-13 Glaxo Group Limited Immunoglobulins
WO2005100387A1 (en) 2004-04-07 2005-10-27 The University Of Chicago Monomeric red fluorescent proteins
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
KR101222413B1 (ko) 2004-05-27 2013-01-16 다니스코 유에스 인크. 아스퍼질러스 가와치 산-안정성 알파 아밀라제의 이종 발현및 입상 전분 가수분해에서의 이용
US7332319B2 (en) 2004-05-27 2008-02-19 Genencor International, Inc. Heterologous alpha amylase expression in Aspergillus
US7413887B2 (en) 2004-05-27 2008-08-19 Genecor International, Inc. Trichoderma reesei glucoamylase and homologs thereof
KR101545424B1 (ko) 2004-05-27 2015-08-18 다니스코 유에스 인크. 입상 전분 가수분해 활성을 가진 산-안정성 알파 아밀라아제 및 효소 조성물
NZ551335A (en) 2004-06-18 2010-03-26 Ambrx Inc Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PL1771474T3 (pl) 2004-07-20 2010-07-30 Genentech Inc Inhibitory białka angiopoetyno-4-podobnego, kombinacje i ich zastosowanie
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
FI118339B (fi) 2004-09-21 2007-10-15 Ab Enzymes Oy Uusi lakkaasientsyymi ja sen käyttö
CA2586313C (en) 2004-11-10 2016-03-08 Diadexus, Inc. Ovr110 antibody compositions and methods of use
KR101423769B1 (ko) 2004-12-22 2014-07-30 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 그와관련된 방법 및 그의 용도
EP2284191A3 (en) 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
ZA200706858B (en) 2005-02-18 2008-10-29 Genencor Int Polypeptides having alpha-amylase and granular starch hydrolyzing activity
ES2400582T3 (es) 2005-03-21 2013-04-10 Virobay, Inc. Compuestos de alfa cetoamida como inhibidores de cisteína proteasa
EP2314668B1 (en) 2005-04-12 2016-11-09 Danisco US Inc. Gene inactivated mutants with altered protein production
US7741093B2 (en) 2005-04-29 2010-06-22 Ab Enzymes Oy Cellulases and their uses
EP2397493A1 (en) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
EP2316930A1 (en) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Human coagulation factor VII polypeptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP2339014B1 (en) 2005-11-16 2015-05-27 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP3023497A1 (en) 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
MX2008008225A (es) 2005-12-22 2008-10-01 Ab Enzymes Oy Nuevas enzimas.
US7256032B2 (en) 2005-12-22 2007-08-14 Ab Enzymes Oy Enzymes
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CA2647107A1 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
US7361487B2 (en) 2006-04-13 2008-04-22 Ab Enzymes Oy Enzyme fusion proteins and their use
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2027291A2 (en) 2006-04-27 2009-02-25 Pikamab, Inc. Methods and compositions for antibody therapy
CA2652452C (en) 2006-05-15 2018-07-31 Sea Lane Biotechnologies, Llc Neutralizing antibodies to influenza viruses
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CA2656063C (en) 2006-06-21 2016-10-18 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
WO2008009545A1 (en) 2006-06-30 2008-01-24 Novo Nordisk A/S Anti-nkg2a antibodies and uses thereof
US20080026376A1 (en) 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
GEP20125612B (en) 2006-08-18 2012-08-27 Novartis Ag Prlr-specific antibody and usage thereof
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
JP5568307B2 (ja) 2006-10-10 2014-08-06 ダニスコ・ユーエス・インク、ジェネンコー・ディビジョン 修飾された性質を有するグルコアミラーゼ変異体
JP5732182B2 (ja) 2006-10-27 2015-06-10 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． 眼疾患と症状を処置するための組成物および方法
ES2524059T3 (es) 2006-10-27 2014-12-03 Lpath, Inc. Composiciones y procedimientos de unión a esfingosina-1-fosfato
CN101965363A (zh) 2006-11-02 2011-02-02 丹尼尔·J·卡鹏 具有活动部分的杂合免疫球蛋白
CN101529255A (zh) 2006-11-14 2009-09-09 健泰科生物技术公司 神经元再生的调控剂
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN101687032A (zh) 2006-12-07 2010-03-31 诺瓦提斯公司 抗ephb3的拮抗剂抗体
KR101431856B1 (ko) 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
US20080220498A1 (en) 2007-03-06 2008-09-11 Cervin Marguerite A Variant Buttiauxella sp. phytases having altered properties
US8143046B2 (en) 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
RU2502806C2 (ru) 2007-02-22 2013-12-27 Дженентек, Инк. Способы выявления воспалительного заболевания кишечника
ES2376059T3 (es) 2007-03-14 2012-03-08 Danisco Us Inc. La a-amilasa de trichoderma reesei es una enzima maltogénica.
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
US8093016B2 (en) 2007-05-21 2012-01-10 Danisco Us Inc. Use of an aspartic protease (NS24) signal sequence for heterologous protein expression
US8158124B2 (en) 2007-05-30 2012-04-17 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
CN101932591B (zh) 2007-07-09 2018-02-16 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原
KR101559595B1 (ko) 2007-07-16 2015-10-12 제넨테크, 인크. 인간화 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
WO2009012268A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009031992A1 (en) * 2007-09-04 2009-03-12 Elizabeth Varriano-Marston Method for controlling banana quality by packaging
CA2699201C (en) 2007-09-12 2017-04-18 Danisco Us Inc. Trichoderma promoter
ES2629440T5 (es) 2007-10-04 2020-11-20 Zymogenetics Inc zB7H6 miembro de la familia B7 y composiciones y métodos relacionados
US8592194B2 (en) 2007-10-09 2013-11-26 Danisco Us Inc. Glucoamylase variants with altered properties
ES2504983T3 (es) 2007-10-09 2014-10-09 Danisco Us Inc. Variantes de glucoamilasa
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
CN103554215B (zh) 2007-10-30 2016-06-15 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
US8158762B2 (en) 2007-11-08 2012-04-17 Genentech, Inc. Anti-factor B antibodies and their uses
KR20100097691A (ko) 2007-11-12 2010-09-03 테라클론 사이언시스, 아이엔씨. 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
WO2010135521A2 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
ES2527586T3 (es) 2007-11-20 2015-01-27 Danisco Us Inc. Variantes de glucoamilasa con propiedades modificadas
WO2009073511A2 (en) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
CA2709107A1 (en) 2007-12-13 2009-06-18 Danisco Us Inc. Compositions and methods for producing isoprene
US8318451B2 (en) 2008-01-02 2012-11-27 Danisco Us Inc. Process of obtaining ethanol without glucoamylase using Pseudomonas saccharophila G4-amylase variants thereof
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2247619A1 (en) 2008-01-24 2010-11-10 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
MX2010008437A (es) 2008-01-31 2010-11-25 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
CN101945996A (zh) 2008-02-11 2011-01-12 丹尼斯科美国公司 来自里氏木霉的具有微生物裂解活性的酶
WO2009114560A2 (en) 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus
AU2009228058A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
MX2010011088A (es) 2008-04-09 2010-11-05 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EP2283124B1 (en) 2008-04-18 2016-05-25 Danisco US Inc. Buttiauxella sp. phytase variants
AU2009240505B2 (en) 2008-04-23 2013-09-05 Danisco Us Inc. Isoprene synthase variants for improved microbial production of isoprene
AU2009244300B2 (en) 2008-05-06 2014-04-17 Genentech, Inc. Affinity matured CRIg variants
JP2011526790A (ja) 2008-07-02 2011-10-20 ダニスコ・ユーエス・インク 分離された条件下および／または安全操業条件下における、ｃ５炭化水素を含まないイソプレン組成物及びその製造方法
PE20110426A1 (es) 2008-07-23 2011-07-01 Ambrx Inc Polipeptidos g-csf bovinos modificados
PT3604324T (pt) 2008-08-14 2024-05-10 Genentech Inc Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena
PE20100269A1 (es) 2008-09-05 2010-04-30 TransAlgae Ltd Resistencia a herbicida para mantener cultivos axenicos por manipulacion genetica
MY169163A (en) 2008-09-15 2019-02-19 Danisco Us Inc Increased isoprene production using the archaeal lower mevalonate pathway
SG169641A1 (en) 2008-09-15 2011-04-29 Danisco Us Inc Systems using cell culture for production of isoprene
SG169614A1 (en) 2008-09-15 2011-04-29 Goodyear Tire & Rubber Conversion of prenyl derivatives to isoprene
ZA201102111B (en) 2008-09-15 2013-10-30 Danisco Us Inc Reduction of carbon dioxide emission during isoprene production by fermentation
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
BRPI0919031A2 (pt) 2008-09-26 2014-09-23 Ambrx Inc Micro-organismos e vacinas dependentes de replicação através do uso de aminoácidos não naturais
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
JP5808249B2 (ja) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
EP2340040B1 (en) 2008-10-22 2019-01-16 F.Hoffmann-La Roche Ag Modulation of axon degeneration
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
EP2346903A1 (en) 2008-11-06 2011-07-27 Glenmark Pharmaceuticals S.A. Treatment with anti-alpha2 integrin antibodies
CN102245764B (zh) 2008-12-15 2014-02-26 丹尼斯科美国公司 杂合α-淀粉酶
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
FI20086236A0 (fi) 2008-12-23 2008-12-23 Valtion Teknillinen Heksuronihapon konversio heksarihapoksi
FI122029B (fi) 2008-12-30 2011-07-29 Ab Enzymes Oy Sieniperäiset endoglukanaasit, niiden tuotto ja käyttö
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
CA2748887A1 (en) 2008-12-30 2010-07-08 Danisco Us Inc. Methods of producing isoprene and a co-product
KR101544245B1 (ko) 2009-02-03 2015-08-12 아뮤닉스 오퍼레이팅 인코포레이티드 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
TW201038286A (en) 2009-04-01 2010-11-01 Genentech Inc Anti-FcRH5 antibodies and immunoconjugates and methods of use
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
CA2759700A1 (en) 2009-04-23 2010-10-28 Danisco Us Inc. Three-dimensional structure of isoprene synthase and its use thereof for generating variants
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
FI121712B (fi) 2009-04-30 2011-03-15 Ab Enzymes Oy Uusi sieniperäinen proteaasi ja sen käyttö
FI121711B (fi) 2009-04-30 2011-03-15 Ab Enzymes Oy Sieniperäinen seriiniproteaasi ja sen käyttö
DK3591046T3 (da) 2009-05-19 2021-07-26 Dupont Nutrition Biosci Aps Amylasepolypeptide
CA2764108A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
NO2440241T3 (es) 2009-06-08 2018-01-06
TWI434921B (zh) 2009-06-17 2014-04-21 Danisco Us Inc 從生物異戊二烯組合物製造燃料成分之方法及系統
TW201412988A (zh) 2009-06-17 2014-04-01 Danisco Us Inc 使用ｄｘｐ及ｍｖａ途徑之改良之異戊二烯製造
FI121851B (fi) 2009-07-08 2011-05-13 Ab Enzymes Oy Sieniperäinen proteaasi ja sen käyttö
SI2454373T1 (sl) 2009-07-15 2015-03-31 Abb Vie Inc. Izboljšanje celične produkcije z mehanotransdukcijo
US20120282285A1 (en) 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
US8765431B2 (en) 2009-07-23 2014-07-01 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
SG178177A1 (en) 2009-07-31 2012-03-29 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
CN102575239B (zh) 2009-08-19 2017-06-16 杜邦营养生物科学有限公司 葡糖淀粉酶的变体
EP2467475A1 (en) 2009-08-19 2012-06-27 Danisco US Inc. Combinatorial variants of glucoamylase with improved specific activity and/or thermostability
EP3222287A1 (en) 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
EP2473522B1 (en) 2009-09-02 2016-08-17 Genentech, Inc. Mutant smoothened and methods of using the same
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
BR112012008907A2 (pt) 2009-10-15 2020-11-24 Genentech, Inc fatores de crescimento de fibroblastos quiméricos com especificidade receptora alterada
SI3037104T1 (sl) 2009-10-20 2020-10-30 Abbvie Inc. Izolacija in prečiščevanje protiteles anti-IL-13 z uporabo afinitetne kromatografije beljakovine A
CN102711826B (zh) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
RU2012120783A (ru) 2009-10-22 2013-11-27 Женентек, Инк. Модуляция дегенерации аксона
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
KR101884028B1 (ko) 2009-11-30 2018-08-01 제넨테크, 인크. Ｓｌｃ３４ａ２ (ｔａｔ２１１ = 서열 ２)를 발현하는 종양의 치료 및 진단을 위한 항체
US9096843B2 (en) 2009-12-01 2015-08-04 Novo Nordisk A/S Peptidyl α-hydroxyglycine α-amidating lyases
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
WO2011073235A1 (en) 2009-12-18 2011-06-23 Csl Ltd. Method of purifying polypeptides
PE20121799A1 (es) 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
FI122937B (fi) 2009-12-30 2012-09-14 Roal Oy Menetelmä selluloosamateriaalin käsittelemiseksi sekä tässä käyttökelpoiset CBH II/Cel6A entsyymit
MY160590A (en) 2010-01-28 2017-03-15 Glaxo Group Ltd Cd127 binding proteins
SG10201501285RA (en) 2010-02-23 2015-04-29 Sanofi Sa Anti-alpha2 integrin antibodies and their uses
PE20130214A1 (es) 2010-02-23 2013-03-11 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
WO2011120993A1 (en) 2010-03-29 2011-10-06 Danisco A/S Polypeptides having transgalactosylating activity
CN102918063B (zh) 2010-03-31 2016-06-29 贝林格尔.英格海姆国际有限公司 抗-cd40抗体
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2576580T3 (en) 2010-05-28 2016-10-17 Hoffmann La Roche LOWERING THE lactate AND INCREASE polypeptide production by downregulation of the expression of lactate dehydrogenase, and PYRUVATDEHYDROGENASEKINASE
WO2011150454A1 (en) 2010-06-01 2011-12-08 Monash University ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
BR112012032276A2 (pt) 2010-06-17 2016-11-16 Danisco Us Inc composições de combustível compreendendo derivados de isopreno
EP2585094B1 (en) 2010-06-25 2018-08-01 INSERM - Institut National de la Santé et de la Recherche Médicale Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections
CA2805035A1 (en) 2010-07-22 2012-01-26 Glaxosmithkline Biologicals S.A. Novel antigen binding proteins
CN103068997A (zh) 2010-08-06 2013-04-24 丹尼斯科美国公司 中性pH糖化和发酵
US20120045812A1 (en) 2010-08-06 2012-02-23 Danisco Us Inc. PRODUCTION OF ISOPRENE UNDER NEUTRAL pH CONDITIONS
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
CA2807664A1 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
EP2603525A1 (en) 2010-08-13 2013-06-19 F.Hoffmann-La Roche Ag Antibodies to il-1beta and il-18, for treatment of disease
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
LT2605789T (lt) 2010-08-17 2019-09-10 Ambrx, Inc. Modifikuoti relaksino polipeptidai ir jų panaudojimas
EP2608682B1 (en) 2010-08-24 2017-12-13 Danisco US Inc. Method of making a snack bar comprising a low temperature rice protein concentrate
SI3556396T1 (sl) 2010-08-31 2022-09-30 Theraclone Sciences, Inc. Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV)
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
AU2011302522A1 (en) 2010-09-15 2013-05-02 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
KR20130114143A (ko) 2010-09-20 2013-10-16 애브비 인코포레이티드 모사 이동층 크로마토그래피를 이용한 항체의 정제
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
ES2588981T3 (es) 2010-10-05 2016-11-08 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
WO2012045275A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with aplastic anemia
US9632098B2 (en) 2010-10-08 2017-04-25 Shanghai Kexin Biotech Co., Ltd. Moesin fragments and uses thereof
US9345764B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
EP2624852B1 (en) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Diagnostic and therapeutic uses of moesin fragments
US9347950B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with immune thrombocytopenia
BR112013010551A8 (pt) 2010-10-27 2018-07-03 Danisco Us Inc variantes de isopreno sintase para produção aprimorada de isopreno
FI123942B (fi) 2010-10-29 2013-12-31 Ab Enzymes Oy Sieniperäisen seriiniproteaasin variantteja
WO2012061448A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
SG190129A1 (en) 2010-11-05 2013-06-28 Abbvie Inc Efficient and effective supplement screening for the development of chemically defined media in cell culture
WO2012099566A1 (en) 2010-11-17 2012-07-26 Sea Lane Biotechnologies, Llc Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
BR112013016235B1 (pt) 2010-12-22 2020-03-31 Cephalon Australia Pty Ltd Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
JP2014502844A (ja) 2010-12-22 2014-02-06 ダニスコ・ユーエス・インク 組み換え細胞による五炭糖の生物学的生産
BR112013018316A2 (pt) 2010-12-22 2018-09-11 Danisco Us Inc composições e métodos para produção aprimorada de isopreno usando dois tipos de enzimas ispg
SG192727A1 (en) 2011-02-14 2013-09-30 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US20140056897A1 (en) 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
US20120315277A1 (en) 2011-03-15 2012-12-13 Theraclone Sciences, Inc. Compositions and Methods for the Therapy and Diagnosis of Influenza
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
EP2689250A1 (en) 2011-03-23 2014-01-29 AbbVie Inc. Methods and systems for the analysis of protein samples
KR102148063B1 (ko) 2011-03-31 2020-08-25 제넨테크, 인크. 베타7 인테그린 길항제를 투여하는 방법
FI123425B (fi) 2011-03-31 2013-04-30 Ab Enzymes Oy Proteaasientsyymi ja sen käytöt
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2702163A1 (en) 2011-04-29 2014-03-05 Danisco US Inc. Single ph process for starch liquefaction and saccharification for high-density glucose syrups
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
EP3954704A1 (en) 2011-06-03 2022-02-16 XOMA Technology Ltd. Antibodies specific for tgf-beta
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
CA2840460C (en) 2011-07-11 2022-08-16 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
US8951764B2 (en) 2011-08-05 2015-02-10 Danisco Us Inc. Production of isoprenoids under neutral pH conditions
JP2014525412A (ja) 2011-08-17 2014-09-29 ジェネンテック， インコーポレイテッド 難治性腫瘍における血管新生の阻害
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
BR112014005744B1 (pt) 2011-09-12 2020-11-17 Amunix Operating Inc. proteína de fusão recombinante, composição farmacêutica compreendendo a referida proteína e uso da mesma referência cruzada com pedido relacionado
JP2014533929A (ja) 2011-09-23 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー ５ｔ４およびｃｄ３に対する二重特異的結合性分子
CA2851855A1 (en) 2011-10-31 2013-05-10 Bp Corporation North America Inc. Use of plant promoters in filamentous fungi
WO2013067028A1 (en) 2011-10-31 2013-05-10 Bp Corporation North America Inc. Use of mammalian promoters in filamentous fungi
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HUE047437T2 (hu) 2011-11-16 2020-04-28 Boehringer Ingelheim Int Anti-IL-36R antitestek
CN110078831A (zh) 2011-12-01 2019-08-02 圆祥生命科技股份有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
BR112014014652B1 (pt) 2011-12-16 2021-07-13 Braskem S.A. Método de produção de butadieno e microrganismo geneticamente modificado
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
PL2794635T3 (pl) 2011-12-22 2019-02-28 F.Hoffmann-La Roche Ag Membranowa chromatografia jonowymienna
BR112014017141A2 (pt) 2012-01-19 2019-09-24 Univ Cincinnati método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
MX2014009043A (es) 2012-01-31 2014-10-14 Genentech Inc Anticuerpos anti-ige y sus metodos de uso.
ES2676029T3 (es) 2012-02-09 2018-07-16 Var2 Pharmaceuticals Aps Direccionamiento de glicanos de sulfato de condroitina
EA201491388A1 (ru) 2012-02-15 2015-01-30 Байоджен Айдек Ма Инк. Рекомбинантные белки фактора viii
SI2814840T1 (sl) 2012-02-15 2020-06-30 Bioverativ Therapeutics Inc. Sestavki faktorja VIII in postopki njihove izdelave in uporabe
WO2013128027A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
DK2841087T3 (da) 2012-04-27 2017-11-20 Us Health Vaskulær endothel-vækstfaktor-antagonister og fremgangsmåder til anvendelse deraf
US9163263B2 (en) 2012-05-02 2015-10-20 The Goodyear Tire & Rubber Company Identification of isoprene synthase variants with improved properties for the production of isoprene
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
CN104334720B (zh) 2012-06-08 2017-05-31 杜邦营养生物科学有限公司 具有转半乳糖基化活性的多肽
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
EP2877197A2 (en) 2012-07-25 2015-06-03 University Of Cincinnati Method of treating type i diabetes using apolipoprotein aiv
MX2015002099A (es) 2012-08-22 2015-05-11 Dupont Nutrition Biosci Aps Variantes que tienen actividad glucoamilasa.
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
WO2014060401A1 (en) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
TR201815254T4 (tr) 2013-01-02 2018-11-21 Glenmark Pharmaceuticals Sa Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
PT2968467T (pt) 2013-03-13 2020-07-28 Hoffmann La Roche Formulações de oxidação reduzida
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
CN104968362B (zh) 2013-03-13 2018-12-14 霍夫曼-拉罗奇有限公司 氧化降低的配制剂
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
EP2970375A1 (en) 2013-03-14 2016-01-20 AbbVie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
AU2013384204B2 (en) 2013-03-14 2017-03-16 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
WO2014151901A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Improvement of mammalian cell culture performance through surfactant supplementation of feed media
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
BR112015021993A8 (pt) 2013-03-15 2019-12-03 Genentech Inc polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
WO2014145768A2 (en) 2013-03-15 2014-09-18 Bp Corporation North America Inc. Use of non-fungal 5' utrs in filamentous fungi
EP3611180B1 (en) 2013-03-15 2021-12-22 Biomolecular Holdings LLC Hybrid immunoglobulin containing non-peptidyl linkage
JP2016513478A (ja) 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
SG11201507974RA (en) 2013-03-27 2015-10-29 Genentech Inc Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP3004162B1 (en) 2013-05-31 2020-03-11 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
UA122478C2 (uk) 2013-09-27 2020-11-25 Дженентек, Інк. Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1
US10203327B2 (en) 2013-11-05 2019-02-12 Novartis Ag Organic compounds
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
MX2016007636A (es) 2013-12-11 2016-10-13 Dupont Nutrition Biosci Aps Metodo para preparar un producto lacteo que tiene un contenido estable de galactooligosacarido(s).
PT3083686T (pt) 2013-12-17 2019-12-18 Hoffmann La Roche Métodos de tratamento de cancros com antagonistas da ligação ao eixo pd-1 e taxanos
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
SG11201604875PA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015102341A1 (ko) 2013-12-30 2015-07-09 재단법인 의약바이오컨버젼스연구단 항 krs 모노클로날 항체 및 이의 용도
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
MX367661B (es) 2014-01-31 2019-08-30 Boehringer Ingelheim Int Anticuerpos anti-baff novedosos.
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
SG10201807877TA (en) 2014-03-14 2018-10-30 Daniel Capon Hybrid immunoglobulin containing non-peptidyl linkage
CN111808276A (zh) 2014-03-25 2020-10-23 豪夫迈·罗氏有限公司 制备用于细胞培养基中的泊洛沙姆的方法
KR102397324B1 (ko) 2014-03-27 2022-05-13 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
WO2015184327A1 (en) 2014-05-30 2015-12-03 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
AU2015295242B2 (en) 2014-07-31 2020-10-22 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
TW201609812A (zh) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 最佳化之跨物種特異性雙特異性單鏈抗體構築體
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
US20160137727A1 (en) 2014-09-15 2016-05-19 Genentech, Inc. Antibody formulations
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
SI3412302T1 (sl) 2014-10-24 2021-09-30 Bristol-Myers Squibb Company Modificirani FGF-21 polipeptidi in njihova uporaba
MX2017005981A (es) 2014-11-07 2017-06-29 Dupont Nutrition Biosci Aps Celula hospedadora recombinante que expresa actividad de beta-galactosidasa y/o transgalactosidante deficiente en mananasa, celulasa y pectinasa.
US20160166685A1 (en) 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
BR112017011325A2 (pt) 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
CA2972995A1 (en) 2015-02-04 2016-08-11 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
KR20220136484A (ko) 2015-02-09 2022-10-07 다니스코 유에스 인크. 진균 균주 및 사용 방법
CN113209289A (zh) 2015-02-26 2021-08-06 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
EP3283109A1 (en) 2015-04-14 2018-02-21 Boehringer Ingelheim International GmbH Methods of treating diseases
TW202311292A (zh) 2015-04-17 2023-03-16 德商安美基研究（慕尼黑）公司 Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
ES2929531T3 (es) 2015-05-22 2022-11-30 Dupont Nutrition Biosci Aps Acetolactato descarboxilasa
MX2017014735A (es) 2015-05-29 2018-03-23 Genentech Inc Metilacion de promotor pd-l1 en cancer.
AU2016280070B2 (en) 2015-06-17 2022-09-15 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP6883579B2 (ja) 2015-08-11 2021-06-09 ウーシー バイオロジクス（ケイマン）インコーポレイテッド 新規抗ｐｄ−１抗体
ES2835067T3 (es) 2015-09-02 2021-06-21 Dupont Nutrition Biosci Aps Glucósido hidrolasas y su uso en la prevención y/o tratamiento de infección patógena en un animal
JP7175760B2 (ja) 2015-09-07 2022-11-21 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） 新規なｉｇｆｒ様レセプター及びその使用
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
BR112018013071A2 (pt) 2015-12-30 2018-12-11 Genentech Inc uso de derivados de triptofano para formulações de proteínas
EP3397287A1 (en) 2015-12-30 2018-11-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
MY195542A (en) 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
ES2905361T3 (es) 2016-02-03 2022-04-08 Amgen Res Munich Gmbh Construcciones de anticuerpo de acoplamiento a linfocitos T biespecíficas para BCMA y CD3
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN109153719B (zh) 2016-03-15 2022-12-30 中外制药株式会社 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
CA3007135A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
EP3744733A3 (en) 2016-04-15 2021-02-24 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
WO2017207694A1 (en) 2016-06-02 2017-12-07 Kohlmann Angelica Antibodies that bind to human anti-müllerian hormone (amh) and their uses
EP3478831B1 (en) 2016-06-30 2021-01-20 Danisco US Inc. Aspartic proteases
CN109803680B (zh) 2016-08-01 2024-05-17 佐马美国有限公司 甲状旁腺激素受体1(pth1r)抗体和其用途
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
BR112019004988A2 (pt) 2016-09-16 2019-06-04 Dupont Nutrition Biosci Aps variantes de decarboxilase de acetolactato que tem atividade específica aprimorada
JP2020502991A (ja) 2016-09-20 2020-01-30 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｐｃｓｋ９抗体
EP3515205A1 (en) 2016-09-23 2019-07-31 DuPont Nutrition Biosciences ApS Use of low ph active alpha-1,4/1,6-glycoside hydrolases as a feed additive for ruminants to enhance starch digestion
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
US10876103B2 (en) 2016-10-04 2020-12-29 Danisco Us Inc Protein production in filamentous fungal cells in the absence of inducing substrates
US20180105588A1 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
WO2018093752A1 (en) 2016-11-15 2018-05-24 Danisco Us Inc. Filamentous fungi with improved protein production
EP3574007A1 (en) 2017-01-30 2019-12-04 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel igfr-like 2 receptor and uses thereof
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3592429A1 (en) 2017-03-06 2020-01-15 DuPont Nutrition Biosciences ApS Novel fungal fucosidases and their use in preventing and/or treating a pathogenic infection in an animal
JP7216424B2 (ja) 2017-03-15 2023-02-01 チンファ ユニバーシティ 新規の抗ＴｒｋＢ抗体
WO2018182284A1 (ko) 2017-03-27 2018-10-04 재단법인 의약바이오컨버젼스연구단 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
CN110461877A (zh) 2017-03-27 2019-11-15 勃林格殷格翰国际有限公司 抗il-36r抗体联合治疗
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
TW201902510A (zh) 2017-05-05 2019-01-16 美商安進公司 用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
CN111315780A (zh) 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EA202091974A1 (ru) 2018-02-21 2020-12-08 Селджин Корпорейшн Связывающие bcma антитела и их применение
KR102340989B1 (ko) 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
US20210171610A1 (en) 2018-05-02 2021-06-10 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
WO2019246557A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
BR112020024078A2 (pt) 2018-06-29 2021-02-17 Boehringer Ingelheim International Gmbh anticorpos anti-cd40 para uso no tratamento de doença autoimune
US20210278406A1 (en) 2018-07-13 2021-09-09 Varct Diagnostic Aps Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
MX2021001453A (es) 2018-08-08 2021-04-12 Genentech Inc Uso de derivados de triptofano y l-metionina para una formulacion de proteinas.
AU2019342133A1 (en) 2018-09-21 2021-04-22 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
WO2020068557A1 (en) 2018-09-25 2020-04-02 BioLegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
CN112703204A (zh) 2018-09-28 2021-04-23 安进公司 针对可溶性bcma的抗体
AR117650A1 (es) 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
MA53980A (fr) 2018-10-23 2022-01-26 Consejo Superior Investigacion Anticorps spécifiques de l'apoj glycosylée et leurs utilisations
JP2022528067A (ja) 2019-03-27 2022-06-08 ユーエムシー ユトレヒト ホールディング ビー．ブイ． 工学的に操作されたＩｇＡ抗体および使用方法
CN113795509A (zh) 2019-05-09 2021-12-14 勃林格殷格翰国际有限公司 抗-sema3a抗体及其用于治疗眼或眼部疾病的用途
CN114206935B (zh) 2019-05-24 2024-01-12 三优生物医药(上海)有限公司 新型cldn18.2结合分子
AU2020290573A1 (en) 2019-06-13 2021-11-04 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
US20220268787A1 (en) 2019-07-18 2022-08-25 Jw Bioscience Antibody specifically binding to wrs protein, and use thereof
CN115551530A (zh) 2019-08-27 2022-12-30 通尼克斯制药有限公司 经修饰的tff2多肽
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
KR102442204B1 (ko) 2019-09-20 2022-09-08 경북대학교 산학협력단 Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
EP4058485A1 (en) 2019-11-13 2022-09-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP4077699A1 (en) 2019-12-19 2022-10-26 Basf Se Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals
CN115135762A (zh) 2019-12-20 2022-09-30 巴斯夫欧洲公司 降低萜烯的毒性和增加微生物的生产潜力
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CN113461817A (zh) 2020-03-31 2021-10-01 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
TW202204601A (zh) 2020-04-15 2022-02-01 美商建南德克公司 銅損失減緩
CA3181776A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
CN115698068A (zh) 2020-06-02 2023-02-03 艾库斯生物科学有限公司 抗tigit抗体
US20210388064A1 (en) 2020-06-15 2021-12-16 Sarepta Therapeutics, Inc. Adeno-associated virus antibodies and fragments thereof
JP2023531406A (ja) 2020-06-16 2023-07-24 ジェネンテック， インコーポレイテッド トリプルネガティブ乳がんを処置するための方法および組成物
EP3939999A1 (en) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022096698A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Polypeptide constructs binding to cd3
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
KR20230098335A (ko) 2020-11-06 2023-07-03 암젠 인크 클리핑 비율이 감소된 항원 결합 도메인
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
MX2023007028A (es) 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.
AR125290A1 (es) 2021-04-02 2023-07-05 Amgen Inc Construcciones de unión a mageb2
WO2023002060A1 (en) 2021-07-23 2023-01-26 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Igfr-l1 antibodies and uses thereof
WO2023105087A1 (en) 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
EP4238988A1 (en) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antibodies against sars-cov-2 and uses thereof
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024083953A1 (en) 2022-10-18 2024-04-25 Tubulis Gmbh Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
US20240182596A1 (en) 2022-10-18 2024-06-06 Tubulis Gmbh Anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338400C (en) * 1983-08-31 1996-06-18 David H. Gelfand Recombinant fungal cellulases
JPS62175183A (ja) * 1985-08-29 1987-07-31 ジエネンコ−　インコ−ポレ−テツド 繊維状菌類中に発現する異種ポリペプチドとその製造方法及びその製造のためのベクタ−
NZ217373A (en) * 1985-08-29 1990-10-26 Genencor Inc Production of heterologous peptide in filamentous fungi, vectors and dna

Also Published As

Publication number Publication date
JP2702924B2 (ja) 1998-01-26
NO871785L (no) 1987-11-02
IE871149L (en) 1987-10-30
FI108358B (fi) 2002-01-15
ES2056817T3 (es) 1994-10-16
FI871908A (fi) 1987-10-31
EP0244234A2 (en) 1987-11-04
DE3786592T2 (de) 1993-11-04
JPS6394981A (ja) 1988-04-26
DE3786592D1 (de) 1993-08-26
JPH08173156A (ja) 1996-07-09
NO871785D0 (no) 1987-04-29
JP2769305B2 (ja) 1998-06-25
EP0244234A3 (en) 1988-10-12
ATE91714T1 (de) 1993-08-15
DK175814B1 (da) 2005-03-07
FI871908A0 (fi) 1987-04-29
DE3786592T3 (de) 2002-05-29
EP0244234B1 (en) 1993-07-21
IE60428B1 (en) 1994-07-13
DK219087A (da) 1987-10-31
EP0244234B2 (en) 2001-11-07
GB8610600D0 (en) 1986-06-04
DK219087D0 (da) 1987-04-29

Similar Documents

Publication Publication Date Title
ES2056817T5 (es) Transformacion de trichoderma.
AU573523B2 (en) Functional human urokinase proteins
DK371087A (da) Mamalialt interleukin-4
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
PT87207A (pt) Process for preparing recombinant htlv-iii proteins and uses thereof
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 244234

Country of ref document: ES